MNKD Mannkind Corp

Price (delayed)

$3.88

Market cap

$979.95M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.37

Enterprise value

$1.3B

MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, its ...

Highlights
The revenue has contracted by 7% from the previous quarter but it has grown by 6% YoY
Mannkind's net income has plunged by 55% YoY and by 16% from the previous quarter
Mannkind's gross margin has decreased by 37% YoY and by 18% QoQ

Key stats

What are the main financial stats of MNKD
Market
Shares outstanding
252.57M
Market cap
$979.95M
Enterprise value
$1.3B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
13.96
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
18.54
Earnings
Revenue
$70M
EBIT
-$78.76M
EBITDA
-$72.64M
Free cash flow
-$82.77M
Per share
EPS
-$0.37
Free cash flow per share
-$0.33
Book value per share
-$0.92
Revenue per share
$0.28
TBVPS
$1.22
Balance sheet
Total assets
$308.32M
Total liabilities
$540.38M
Debt
$385.37M
Equity
-$232.06M
Working capital
$130.77M
Liquidity
Debt to equity
-1.66
Current ratio
3.44
Quick ratio
3.22
Net debt/EBITDA
-4.38
Margins
EBITDA margin
-103.8%
Gross margin
39.6%
Net margin
-134.3%
Operating margin
-95.4%
Efficiency
Return on assets
-33.6%
Return on equity
N/A
Return on invested capital
-16.3%
Return on capital employed
-30.9%
Return on sales
-112.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MNKD stock price

How has the Mannkind stock price performed over time
Intraday
-2.51%
1 week
8.99%
1 month
-3%
1 year
-17.62%
YTD
-11.21%
QTD
5.43%

Financial performance

How have Mannkind's revenue and profit performed over time
Revenue
$70M
Gross profit
$27.75M
Operating income
-$66.8M
Net income
-$94.01M
Gross margin
39.6%
Net margin
-134.3%
MNKD's operating income has shrunk by 63% YoY and by 25% QoQ
Mannkind's net income has plunged by 55% YoY and by 16% from the previous quarter
MNKD's operating margin has dropped by 54% year-on-year and by 34% since the previous quarter
The company's net margin fell by 46% YoY and by 25% QoQ

Growth

What is Mannkind's growth rate over time

Valuation

What is Mannkind stock price valuation
P/E
N/A
P/B
N/A
P/S
13.96
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
18.54
Mannkind's EPS has decreased by 37% YoY and by 16% from the previous quarter
The equity has declined by 34% year-on-year and by 11% since the previous quarter
The P/S is 27% higher than the 5-year quarterly average of 11.0 but 6% lower than the last 4 quarters average of 14.8
The revenue has contracted by 7% from the previous quarter but it has grown by 6% YoY

Efficiency

How efficient is Mannkind business performance
Mannkind's ROS has plunged by 57% YoY and by 32% from the previous quarter
The company's return on invested capital has surged by 51% YoY but it fell by 7% QoQ
The ROA is down by 17% QoQ but it is up by 13% YoY

Dividends

What is MNKD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MNKD.

Financial health

How did Mannkind financials performed over time
The company's total assets is 43% lower than its total liabilities
Mannkind's quick ratio has decreased by 25% QoQ and by 16% YoY
The company's current ratio fell by 24% QoQ and by 13% YoY
The equity has declined by 34% year-on-year and by 11% since the previous quarter
The company's debt rose by 16% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.